The preimplantation genetic diagnosis market in Asia is highly fragmented. The different regulatory frameworks regarding preimplantation genetic diagnosis across Asia are responsible for the diversity and large number of companies in the Asia preimplantation genetic diagnosis market. The market is likely to remain dominated by region-specific players in the coming years. According to Transparency Market Research (TMR), the Asia preimplantation genetic diagnosis market is expected to rise to a valuation of US$28.8 mn by 2023.
Rising Demand for Late Conception Drives Demand for Preimplantation Genetic Diagnosis
One of the most important drivers for the Asia preimplantation genetic diagnosis market is the rising number of women preferring to conceive later than the conventional age of motherhood. Many women in countries such as India and China are delaying their pregnancies till the 30s. The increasing demographic of informed, urban women is thus likely to remain a key consumer in the Asia preimplantation genetic diagnosis market, as this demographic is informed enough to check for genetic abnormalities in their fetuses. Conceiving at a later age also increases the risk to the fetus, which is a key reason for the increased use of preimplantation genetic diagnosis services.
The rising prevalence of genetic disorders is another key driver for the preimplantation genetic diagnosis market. While late pregnancies have an increased chance of defects, the incidence of chromosomal aberrations is increasing in regular births as well. This has become an influential factor for the Asia preimplantation genetic diagnosis market and is likely to drive the market in the coming years. The rising impact of lifestyle hazards such as smoking and pollution has also contributed to the rising prevalence of genetic conditions and is thus likely to remain an important driver for the Asia preimplantation genetic diagnosis market.
On the other hand, the social stigma in some regions around preimplantation genetic diagnosis has restrained the market to some extent. The risk of preimplantation genetic diagnosis being abused for female feticide is another risk shadowing the Asia preimplantation genetic diagnosis market’s growth. In many regions, preimplantation genetic diagnosis lacks insurance support, which has also reduced the number of women availing it.
Fertility Clinics to Remain Largest End User of Preimplantation Genetic Diagnosis Services
By end use, the global preimplantation genetic diagnosis market is segmented into healthcare facilities such as hospitals and diagnostic centers, fertility clinics, and academic institutes and research centers. Of these, fertility clinics are expected to account for a significant share of the Asia preimplantation genetic diagnosis market in the coming years. Fertility clinics account for around 50% of the Asia preimplantation genetic diagnosis market and are expected to be valued at US$14.4 mn by 2023. However, the healthcare facilities segment is expected to exhibit the fastest CAGR in the 2015-2023 forecast period: 7.8%
By test type, aneuploidy screening accounts for a leading share of the Asia preimplantation genetic diagnosis market. Despite a reduction in its share over the forecast period, the segment is expected to be valued at US$8.9 mn by 2023 and dominate the Asia preimplantation genetic diagnosis market. Single gene disorder screening is likely to gain demand at a rapid pace in the Asia preimplantation genetic diagnosis market in the coming years, with the segment expected to exhibit an 8.4% CAGR from 2015 to 2023. Other key applications of preimplantation genetic diagnosis include gender selection, detection of chromosomal aberrations, HLA typing, and X-linked diseases.
This review of the market is based on a recent market research report published by Transparency Market Research, titled “Preimplantation Genetic Diagnosis Market - Asia Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.”
For the purpose of this study, the market has been segmented into:
Asia Preimplantation Genetic Diagnosis (PGD) Market, by Test Type
- PGD for Aneuploidy Screening
- PGD for Chromosomal Aberrations
- PGD for Gender Selection
- PGD for HLA Typing
- PGD for Single Gene Disorder
- PGD for X-linked diseases
Asia Preimplantation Genetic Diagnosis (PGD) Market, by End-user
- Fertility Clinics
- Health Care Facilities (including hospitals, diagnostic centers, and health care facilities)
- Academic Institutes and Research Centers
Asia Preimplantation Genetic Diagnosis (PGD) Market, by Geography
- South Eastern Asia
- Eastern Asia
- Southern Asia
- Central Asia
- Western Asia
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453